SOURCE: BIOLASE Technology, Inc.

BIOLASE Technology, Inc.

September 30, 2010 09:00 ET

BIOLASE Announces Appointment of Chief Executive Officer

Search Is Commenced for Chief Financial Officer / Chief Operating Officer Position

IRVINE, CA--(Marketwire - September 30, 2010) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, is pleased to announce that its Board of Directors has appointed Federico Pignatelli the permanent Chief Executive Officer of BIOLASE. Previously, Pignatelli was the interim Chief Executive Officer of BIOLASE. Pignatelli has agreed to continue at an annual salary compensation of $1.00 as Chief Executive Officer. 

Pignatelli is the Chairman of the Board of BIOLASE, and has served, over the past 16 years, in the capacities of Executive Chairman, Interim CEO, and President.

Pignatelli stated, "I am pleased to accept the position as the Chief Executive Officer of BIOLASE. I thank the Board of Directors for its confidence in my leadership. I am looking forward to building significant value for our revolutionary and patented Waterlase® YSGG technology and our cutting edge diode products. I am firmly dedicated to substantially furthering BIOLASE's innovative technology in the dental field and in medicine."

The Company also announced that it commenced an official search for a Chief Financial Officer / Chief Operating Officer position. The Board of Directors expects to make an appointment to this role following a thorough and robust executive search process.

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at, Twitter at, and YouTube at

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Jill Bertotti (investors)
    Len Hall (media)
    Allen & Caron